By John L. LaMattina
An expert's view on fixing the demanding situations confronting modern pharmaceutical industry
Author John LaMattina, a thirty-year veteran of the pharmaceutical and previous president of Pfizer's international R&D department, is the world over famous as knowledgeable at the pharmaceutical undefined. His first ebook, Drug Truths: Dispelling the Myths approximately Pharma R&D, used to be significantly acclaimed for clearing up misconceptions in regards to the pharmaceutical and offering a good account of the contributions of pharmaceutical examine and improvement to human wellbeing and fitness and well-being.
As he toured the rustic discussing Drug Truths, Dr. LaMattina frequently stumbled on those that have been jam-packed with anger, accusing the pharmaceutical of constructing up ailments, hiding risky unwanted effects, and extra. This booklet used to be written based on that have, significantly interpreting public perceptions and realities.
Starting with "4 secrets and techniques that Drug businesses don't desire You to Know," Devalued and Distrusted presents a fact-based account of ways the pharmaceutical works and the demanding situations it faces. It addresses such severe concerns as:
- Why pharmaceutical R&D productiveness has declined
- Where pharmaceutical businesses have to make investments their resources
- What might be performed to resolve middle overall healthiness demanding situations, together with melanoma, diabetes, and neurodegenerative diseases
- How the pharmaceutical can regain public belief and resuscitate its image
Our knowing of human well-being and ailment grows day-by-day; even if, changing technological know-how into medication is more and more demanding. interpreting Devalued and Distrusted, you are going to not just achieve a better appreciation of these demanding situations, but in addition the position that the pharmaceutical at the moment performs and will play in fixing these challenges.
Get to grasp the author: learn an interview with John LaMattina or watch a video on ChemistryViews!
Interview: John LaMattina: 30 Years in Pharma
Video: Can the Pharmaceutical Restory its damaged Image?
Read Online or Download Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image? PDF
Similar pharmacology books
Concentrating on the 3 most crucial elements that effectively deliver an API to market-process improvement, production, and governmental rules and approval-this reference serves as a step by step consultant to the making plans and transparent realizing of the majority production of APIs. This consultant deals present and well timed discussions of the method improvement cycle, layout engineering, the approval method, quality controls and insurance, and validation, in addition to plant production actions together with fabrics administration, upkeep, and safeguard.
Major development has been made within the learn of three-d quantitative structure-activity relationships (3D QSAR) because the first booklet through Richard Cramer in 1988 and the 1st quantity within the sequence. 3D QSAR in Drug layout. idea, equipment and functions, released in 1993. the purpose of that early booklet used to be to give a contribution to the certainty and the additional program of CoMFA and similar methods and to facilitate the fitting use of those equipment.
- Molecular Neuropharmacology: Strategies and Methods
- Bupropion - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Xanax - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Receptor - Based Drug Design (Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs)
- The Pharmacology of the Urinary Tract
Additional resources for Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?
Not only is the goal to eliminate duplicate programs, but also information is gathered as to which research sites can be eliminated, what therapeutic areas of research can be exited, which clinical programs are not a strategic fit for the new company, who will lead the new organization, and so on. Against this backdrop, one can understand how things can slow down. For example, during this period which can take at least nine months, generally no new programs are started. This makes sense in that if the company has set cost targets for R&D for the new organization, one does not want to start new studies in programs that might be dropped six months later.
On this latter point, the FDA wants to see outcome studies—studies in which patients on the drug are followed for multiple years to see what the impact of the drug is on heart attacks and strokes. Such a request is not unreasonable. After all, a drug that causes weight loss should, at the very least, not increase heart attacks and, in theory, should cause a reduction of heart disease. The requirement of such an outcomes study has caused the biopharmaceutical industry to shy away from this disease area.
He also had doubts about the FDA’s desire to approve new drugs to treat obesity, writing: In the past year, the FDA rejected three separate drugs to treat obesity, including one for which the FDA’s own advisory panel recommended approval. As a result, no venture capital firm will now finance a new effort to develop a drug for the obesity epidemic. Freund is not alone in these views. The CEO of the French pharmaceutical company Sanofi, Chris Viehbacher, echoed these same sentiments. 19 His concern is that companies cannot predict how the FDA will weigh the risk–benefit for drugs to treat diabetes and obesity.